A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax
In the United States, children receive primary doses of M-M-RII (Merck & Co, Inc, West Point, PA) and Varivax (Merck & Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates...
Gespeichert in:
| Veröffentlicht in: | Pediatrics (Evanston) 2006-02, Vol.117 (2), p.265-272 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 272 |
|---|---|
| container_issue | 2 |
| container_start_page | 265 |
| container_title | Pediatrics (Evanston) |
| container_volume | 117 |
| creator | Reisinger, Keith S Hoffman Brown, Michelle L Xu, Jin Sullivan, Bradley J Marshall, Gary S Nauert, Beth Matson, David O Silas, Peter E Protocol 014 Study Group for ProQuad Schodel, Florian Gress, Jacqueline O Kuter, Barbara J |
| description | In the United States, children receive primary doses of M-M-RII (Merck & Co, Inc, West Point, PA) and Varivax (Merck & Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates and to reduce the number of individuals without detectable antibodies. A second dose of a varicella-containing vaccine may result in similar benefits.
To demonstrate that ProQuad (measles, mumps, rubella, and varicella virus vaccine live; Merck & Co, Inc) may be given in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.
Four- to 6-year-old children who had been immunized previously with M-M-RII and Varivax were assigned randomly to receive either ProQuad and placebo (N = 399), M-M-RII and placebo (N = 195), or M-M-RII and Varivax (N = 205) and were then monitored for safety and immunogenicity.
ProQuad was generally well tolerated. Similarity (noninferiority) was demonstrated in postvaccination antibody responses to measles, mumps, and rubella between recipients of ProQuad and all recipients of M-M-RII and in responses to varicella between recipients of ProQuad and recipients of Varivax. Postvaccination seropositivity rates for antibodies against all 4 viruses were nearly 100% in all 3 groups. Small fold increases were observed for measles, mumps, and rubella antibody titers. In contrast, substantial boosts in varicella antibody titers were observed among recipients of a second dose of varicella vaccine, administered as ProQuad or Varivax.
ProQuad may be used in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children. |
| doi_str_mv | 10.1542/peds.2005-0092 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_67625932</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A142873357</galeid><sourcerecordid>A142873357</sourcerecordid><originalsourceid>FETCH-LOGICAL-c569t-74a77384f769cf7b2874565f4393bba30ba4cbc621310a0e75ba01c5574625713</originalsourceid><addsrcrecordid>eNqFkltrFDEUxwdRbK2--ihBqFhoaq6Tmcey6LawS2vxgk8hkzmzm5KdWZOZ2n4bP6oZd7FWFiSQc5L8Ts6Ff5a9pOSESsHeraGOJ4wQiQkp2aNsn5KywIIp-TjbJ4RTLNLjXvYsxmtCiJCKPc32aC4k44LvZz9P0aRbVa41vetaNAcTPcRjNB9W62Suhgq8N8fItDX6YoKz4zF51roW0NvL0H0cTH2Epu4GWtR3SOBxz_E3MAFf-BqdgfH98g5Nls7XIUGbYNNDjS4D3LhuiP4OfXX9Es3xHF-dn__JdmNun2dPGuMjvNjag-zzh_efJmd4djE9n5zOsJV52WMljFK8EI3KS9uoihVKyFw2gpe8qgwnlRG2sjmjnBJDQMnKEGqlVCJnUlF-kL3Z_LsO3fcBYq9XLv7utoVUoc5V4krO_gvSsqBFIfIEvv4HvO6G0KYmNGMFl0WZlwnCG2hhPGjXNl0fjF1AC8H4roXGpetTKlI_nEuV-JMdfFo1rJzdGXD0ICAxPdz2CzPEqIvp7CGLd7G28x4WoNO8Jxc7i7GhizFAo9fBrUy405ToUZ56lKce5alHeaaAV9uRDNUK6nt8q8cEHG4BE63xTTCtdfGeU1JQScl95qVbLH-4AGMmZ_ok0PiXS6nSTLNc8l8bL_gJ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>228358969</pqid></control><display><type>article</type><title>A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Reisinger, Keith S ; Hoffman Brown, Michelle L ; Xu, Jin ; Sullivan, Bradley J ; Marshall, Gary S ; Nauert, Beth ; Matson, David O ; Silas, Peter E ; Protocol 014 Study Group for ProQuad ; Schodel, Florian ; Gress, Jacqueline O ; Kuter, Barbara J</creator><creatorcontrib>Reisinger, Keith S ; Hoffman Brown, Michelle L ; Xu, Jin ; Sullivan, Bradley J ; Marshall, Gary S ; Nauert, Beth ; Matson, David O ; Silas, Peter E ; Protocol 014 Study Group for ProQuad ; Schodel, Florian ; Gress, Jacqueline O ; Kuter, Barbara J ; Protocol 014 Study Group for ProQuad</creatorcontrib><description>In the United States, children receive primary doses of M-M-RII (Merck & Co, Inc, West Point, PA) and Varivax (Merck & Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates and to reduce the number of individuals without detectable antibodies. A second dose of a varicella-containing vaccine may result in similar benefits.
To demonstrate that ProQuad (measles, mumps, rubella, and varicella virus vaccine live; Merck & Co, Inc) may be given in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.
Four- to 6-year-old children who had been immunized previously with M-M-RII and Varivax were assigned randomly to receive either ProQuad and placebo (N = 399), M-M-RII and placebo (N = 195), or M-M-RII and Varivax (N = 205) and were then monitored for safety and immunogenicity.
ProQuad was generally well tolerated. Similarity (noninferiority) was demonstrated in postvaccination antibody responses to measles, mumps, and rubella between recipients of ProQuad and all recipients of M-M-RII and in responses to varicella between recipients of ProQuad and recipients of Varivax. Postvaccination seropositivity rates for antibodies against all 4 viruses were nearly 100% in all 3 groups. Small fold increases were observed for measles, mumps, and rubella antibody titers. In contrast, substantial boosts in varicella antibody titers were observed among recipients of a second dose of varicella vaccine, administered as ProQuad or Varivax.
ProQuad may be used in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.</description><identifier>ISSN: 0031-4005</identifier><identifier>EISSN: 1098-4275</identifier><identifier>DOI: 10.1542/peds.2005-0092</identifier><identifier>PMID: 16452343</identifier><identifier>CODEN: PEDIAU</identifier><language>eng</language><publisher>Elk Grove Village, IL: Am Acad Pediatrics</publisher><subject>Antibodies, Viral - blood ; Antiviral drugs ; Biological and medical sciences ; Chickenpox - immunology ; Chickenpox Vaccine - adverse effects ; Chickenpox Vaccine - immunology ; Child ; Child, Preschool ; Children ; Double-Blind Method ; Female ; General aspects ; Health aspects ; Health care ; Human viral diseases ; Humans ; Immunization ; Immunization, Secondary ; Infectious diseases ; Male ; Measles ; Measles virus - immunology ; Measles-Mumps-Rubella Vaccine - adverse effects ; Measles-Mumps-Rubella Vaccine - immunology ; Medical sciences ; Mumps virus - immunology ; Pediatrics ; Rubella virus - immunology ; Vaccination ; Vaccination of children ; Vaccines ; Vaccines, Combined - adverse effects ; Vaccines, Combined - immunology ; Varicella-zoster virus ; Viral diseases ; Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye ; Viruses</subject><ispartof>Pediatrics (Evanston), 2006-02, Vol.117 (2), p.265-272</ispartof><rights>2006 INIST-CNRS</rights><rights>COPYRIGHT 2006 American Academy of Pediatrics</rights><rights>Copyright American Academy of Pediatrics Feb 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c569t-74a77384f769cf7b2874565f4393bba30ba4cbc621310a0e75ba01c5574625713</citedby><cites>FETCH-LOGICAL-c569t-74a77384f769cf7b2874565f4393bba30ba4cbc621310a0e75ba01c5574625713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17541510$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16452343$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reisinger, Keith S</creatorcontrib><creatorcontrib>Hoffman Brown, Michelle L</creatorcontrib><creatorcontrib>Xu, Jin</creatorcontrib><creatorcontrib>Sullivan, Bradley J</creatorcontrib><creatorcontrib>Marshall, Gary S</creatorcontrib><creatorcontrib>Nauert, Beth</creatorcontrib><creatorcontrib>Matson, David O</creatorcontrib><creatorcontrib>Silas, Peter E</creatorcontrib><creatorcontrib>Protocol 014 Study Group for ProQuad</creatorcontrib><creatorcontrib>Schodel, Florian</creatorcontrib><creatorcontrib>Gress, Jacqueline O</creatorcontrib><creatorcontrib>Kuter, Barbara J</creatorcontrib><creatorcontrib>Protocol 014 Study Group for ProQuad</creatorcontrib><title>A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax</title><title>Pediatrics (Evanston)</title><addtitle>Pediatrics</addtitle><description>In the United States, children receive primary doses of M-M-RII (Merck & Co, Inc, West Point, PA) and Varivax (Merck & Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates and to reduce the number of individuals without detectable antibodies. A second dose of a varicella-containing vaccine may result in similar benefits.
To demonstrate that ProQuad (measles, mumps, rubella, and varicella virus vaccine live; Merck & Co, Inc) may be given in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.
Four- to 6-year-old children who had been immunized previously with M-M-RII and Varivax were assigned randomly to receive either ProQuad and placebo (N = 399), M-M-RII and placebo (N = 195), or M-M-RII and Varivax (N = 205) and were then monitored for safety and immunogenicity.
ProQuad was generally well tolerated. Similarity (noninferiority) was demonstrated in postvaccination antibody responses to measles, mumps, and rubella between recipients of ProQuad and all recipients of M-M-RII and in responses to varicella between recipients of ProQuad and recipients of Varivax. Postvaccination seropositivity rates for antibodies against all 4 viruses were nearly 100% in all 3 groups. Small fold increases were observed for measles, mumps, and rubella antibody titers. In contrast, substantial boosts in varicella antibody titers were observed among recipients of a second dose of varicella vaccine, administered as ProQuad or Varivax.
ProQuad may be used in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.</description><subject>Antibodies, Viral - blood</subject><subject>Antiviral drugs</subject><subject>Biological and medical sciences</subject><subject>Chickenpox - immunology</subject><subject>Chickenpox Vaccine - adverse effects</subject><subject>Chickenpox Vaccine - immunology</subject><subject>Child</subject><subject>Child, Preschool</subject><subject>Children</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>General aspects</subject><subject>Health aspects</subject><subject>Health care</subject><subject>Human viral diseases</subject><subject>Humans</subject><subject>Immunization</subject><subject>Immunization, Secondary</subject><subject>Infectious diseases</subject><subject>Male</subject><subject>Measles</subject><subject>Measles virus - immunology</subject><subject>Measles-Mumps-Rubella Vaccine - adverse effects</subject><subject>Measles-Mumps-Rubella Vaccine - immunology</subject><subject>Medical sciences</subject><subject>Mumps virus - immunology</subject><subject>Pediatrics</subject><subject>Rubella virus - immunology</subject><subject>Vaccination</subject><subject>Vaccination of children</subject><subject>Vaccines</subject><subject>Vaccines, Combined - adverse effects</subject><subject>Vaccines, Combined - immunology</subject><subject>Varicella-zoster virus</subject><subject>Viral diseases</subject><subject>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</subject><subject>Viruses</subject><issn>0031-4005</issn><issn>1098-4275</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkltrFDEUxwdRbK2--ihBqFhoaq6Tmcey6LawS2vxgk8hkzmzm5KdWZOZ2n4bP6oZd7FWFiSQc5L8Ts6Ff5a9pOSESsHeraGOJ4wQiQkp2aNsn5KywIIp-TjbJ4RTLNLjXvYsxmtCiJCKPc32aC4k44LvZz9P0aRbVa41vetaNAcTPcRjNB9W62Suhgq8N8fItDX6YoKz4zF51roW0NvL0H0cTH2Epu4GWtR3SOBxz_E3MAFf-BqdgfH98g5Nls7XIUGbYNNDjS4D3LhuiP4OfXX9Es3xHF-dn__JdmNun2dPGuMjvNjag-zzh_efJmd4djE9n5zOsJV52WMljFK8EI3KS9uoihVKyFw2gpe8qgwnlRG2sjmjnBJDQMnKEGqlVCJnUlF-kL3Z_LsO3fcBYq9XLv7utoVUoc5V4krO_gvSsqBFIfIEvv4HvO6G0KYmNGMFl0WZlwnCG2hhPGjXNl0fjF1AC8H4roXGpetTKlI_nEuV-JMdfFo1rJzdGXD0ICAxPdz2CzPEqIvp7CGLd7G28x4WoNO8Jxc7i7GhizFAo9fBrUy405ToUZ56lKce5alHeaaAV9uRDNUK6nt8q8cEHG4BE63xTTCtdfGeU1JQScl95qVbLH-4AGMmZ_ok0PiXS6nSTLNc8l8bL_gJ</recordid><startdate>20060201</startdate><enddate>20060201</enddate><creator>Reisinger, Keith S</creator><creator>Hoffman Brown, Michelle L</creator><creator>Xu, Jin</creator><creator>Sullivan, Bradley J</creator><creator>Marshall, Gary S</creator><creator>Nauert, Beth</creator><creator>Matson, David O</creator><creator>Silas, Peter E</creator><creator>Protocol 014 Study Group for ProQuad</creator><creator>Schodel, Florian</creator><creator>Gress, Jacqueline O</creator><creator>Kuter, Barbara J</creator><general>Am Acad Pediatrics</general><general>American Academy of Pediatrics</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>8GL</scope><scope>7TS</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>U9A</scope><scope>7T5</scope><scope>7X8</scope></search><sort><creationdate>20060201</creationdate><title>A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax</title><author>Reisinger, Keith S ; Hoffman Brown, Michelle L ; Xu, Jin ; Sullivan, Bradley J ; Marshall, Gary S ; Nauert, Beth ; Matson, David O ; Silas, Peter E ; Protocol 014 Study Group for ProQuad ; Schodel, Florian ; Gress, Jacqueline O ; Kuter, Barbara J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c569t-74a77384f769cf7b2874565f4393bba30ba4cbc621310a0e75ba01c5574625713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Antibodies, Viral - blood</topic><topic>Antiviral drugs</topic><topic>Biological and medical sciences</topic><topic>Chickenpox - immunology</topic><topic>Chickenpox Vaccine - adverse effects</topic><topic>Chickenpox Vaccine - immunology</topic><topic>Child</topic><topic>Child, Preschool</topic><topic>Children</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>General aspects</topic><topic>Health aspects</topic><topic>Health care</topic><topic>Human viral diseases</topic><topic>Humans</topic><topic>Immunization</topic><topic>Immunization, Secondary</topic><topic>Infectious diseases</topic><topic>Male</topic><topic>Measles</topic><topic>Measles virus - immunology</topic><topic>Measles-Mumps-Rubella Vaccine - adverse effects</topic><topic>Measles-Mumps-Rubella Vaccine - immunology</topic><topic>Medical sciences</topic><topic>Mumps virus - immunology</topic><topic>Pediatrics</topic><topic>Rubella virus - immunology</topic><topic>Vaccination</topic><topic>Vaccination of children</topic><topic>Vaccines</topic><topic>Vaccines, Combined - adverse effects</topic><topic>Vaccines, Combined - immunology</topic><topic>Varicella-zoster virus</topic><topic>Viral diseases</topic><topic>Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reisinger, Keith S</creatorcontrib><creatorcontrib>Hoffman Brown, Michelle L</creatorcontrib><creatorcontrib>Xu, Jin</creatorcontrib><creatorcontrib>Sullivan, Bradley J</creatorcontrib><creatorcontrib>Marshall, Gary S</creatorcontrib><creatorcontrib>Nauert, Beth</creatorcontrib><creatorcontrib>Matson, David O</creatorcontrib><creatorcontrib>Silas, Peter E</creatorcontrib><creatorcontrib>Protocol 014 Study Group for ProQuad</creatorcontrib><creatorcontrib>Schodel, Florian</creatorcontrib><creatorcontrib>Gress, Jacqueline O</creatorcontrib><creatorcontrib>Kuter, Barbara J</creatorcontrib><creatorcontrib>Protocol 014 Study Group for ProQuad</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: High School</collection><collection>Physical Education Index</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Immunology Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Pediatrics (Evanston)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reisinger, Keith S</au><au>Hoffman Brown, Michelle L</au><au>Xu, Jin</au><au>Sullivan, Bradley J</au><au>Marshall, Gary S</au><au>Nauert, Beth</au><au>Matson, David O</au><au>Silas, Peter E</au><au>Protocol 014 Study Group for ProQuad</au><au>Schodel, Florian</au><au>Gress, Jacqueline O</au><au>Kuter, Barbara J</au><aucorp>Protocol 014 Study Group for ProQuad</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax</atitle><jtitle>Pediatrics (Evanston)</jtitle><addtitle>Pediatrics</addtitle><date>2006-02-01</date><risdate>2006</risdate><volume>117</volume><issue>2</issue><spage>265</spage><epage>272</epage><pages>265-272</pages><issn>0031-4005</issn><eissn>1098-4275</eissn><coden>PEDIAU</coden><abstract>In the United States, children receive primary doses of M-M-RII (Merck & Co, Inc, West Point, PA) and Varivax (Merck & Co, Inc) beginning at 12 months, often at the same health care visit. Currently a second dose of M-M-RII is given to 4- to 6-year-old children, to increase vaccination rates and to reduce the number of individuals without detectable antibodies. A second dose of a varicella-containing vaccine may result in similar benefits.
To demonstrate that ProQuad (measles, mumps, rubella, and varicella virus vaccine live; Merck & Co, Inc) may be given in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.
Four- to 6-year-old children who had been immunized previously with M-M-RII and Varivax were assigned randomly to receive either ProQuad and placebo (N = 399), M-M-RII and placebo (N = 195), or M-M-RII and Varivax (N = 205) and were then monitored for safety and immunogenicity.
ProQuad was generally well tolerated. Similarity (noninferiority) was demonstrated in postvaccination antibody responses to measles, mumps, and rubella between recipients of ProQuad and all recipients of M-M-RII and in responses to varicella between recipients of ProQuad and recipients of Varivax. Postvaccination seropositivity rates for antibodies against all 4 viruses were nearly 100% in all 3 groups. Small fold increases were observed for measles, mumps, and rubella antibody titers. In contrast, substantial boosts in varicella antibody titers were observed among recipients of a second dose of varicella vaccine, administered as ProQuad or Varivax.
ProQuad may be used in place of a second dose of M-M-RII or second doses of M-M-RII and Varivax for 4- to 6-year-old children.</abstract><cop>Elk Grove Village, IL</cop><pub>Am Acad Pediatrics</pub><pmid>16452343</pmid><doi>10.1542/peds.2005-0092</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0031-4005 |
| ispartof | Pediatrics (Evanston), 2006-02, Vol.117 (2), p.265-272 |
| issn | 0031-4005 1098-4275 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67625932 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Antibodies, Viral - blood Antiviral drugs Biological and medical sciences Chickenpox - immunology Chickenpox Vaccine - adverse effects Chickenpox Vaccine - immunology Child Child, Preschool Children Double-Blind Method Female General aspects Health aspects Health care Human viral diseases Humans Immunization Immunization, Secondary Infectious diseases Male Measles Measles virus - immunology Measles-Mumps-Rubella Vaccine - adverse effects Measles-Mumps-Rubella Vaccine - immunology Medical sciences Mumps virus - immunology Pediatrics Rubella virus - immunology Vaccination Vaccination of children Vaccines Vaccines, Combined - adverse effects Vaccines, Combined - immunology Varicella-zoster virus Viral diseases Viral diseases with cutaneous or mucosal lesions and viral diseases of the eye Viruses |
| title | A Combination Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) Given to 4- to 6-Year-Old Healthy Children Vaccinated Previously With M-M-RII and Varivax |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T20%3A12%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Combination%20Measles,%20Mumps,%20Rubella,%20and%20Varicella%20Vaccine%20(ProQuad)%20Given%20to%204-%20to%206-Year-Old%20Healthy%20Children%20Vaccinated%20Previously%20With%20M-M-RII%20and%20Varivax&rft.jtitle=Pediatrics%20(Evanston)&rft.au=Reisinger,%20Keith%20S&rft.aucorp=Protocol%20014%20Study%20Group%20for%20ProQuad&rft.date=2006-02-01&rft.volume=117&rft.issue=2&rft.spage=265&rft.epage=272&rft.pages=265-272&rft.issn=0031-4005&rft.eissn=1098-4275&rft.coden=PEDIAU&rft_id=info:doi/10.1542/peds.2005-0092&rft_dat=%3Cgale_proqu%3EA142873357%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=228358969&rft_id=info:pmid/16452343&rft_galeid=A142873357&rfr_iscdi=true |